Ryan Michael Porter, PhD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Med Endo

Cancer Research Interest

• Research Interest Statement: My lab is focused on musculoskeletal regenerative medicine, with particularly emphasis on the appendicular skeleton (long bones and synovial joints). Within this general theme, there are multiple directions with relevance to cancer therapy. For example, we are interested in improving the management of skeletal defects that result from surgical tumor removal or radiation therapy. Some of this work involves the application of culture-expanded mesenchymal stem cells and their secreted extracellular vesicles for improving defect repair; for patients that have undergone cancer treatment, it will be critical to understand the potential of these exogenous biologics for promoting cancer recurrence. In addition to stem cell-based therapeutics, we are also developing drug delivery strategies that target cartilage; such strategies have the potential to improve drug targeting of skeletal cancers (e.g., chondrosarcoma, osteosarcoma).

Contact Information

• Email Address: RMPORTER@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases – 1R01AR075121
  “Intra-cartilage depot delivery of electrically-charged IL-1RA for targeting osteoarthritis-associated inflammation and catabolism in multiple joint tissues ”
  Principal Investigator
  9/21/2020 – 7/31/2025

Recent Publications

• Warren A, Porter RM, Reyes-Castro O, [et al.]. The NAD salvage pathway in mesenchymal cells is indispensable for skeletal development in mice. Nature communications. 2023 14(1):3616. PMID: 37330524. PMCID: PMC10276814.
• Williams T, Salmanian G, Burns M, [et al., including Porter RM]. Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications. Biochimie. 2022. PMID: 36427681.
• Panos JA, Coenen MJ, Nagelli CV, [et al., including Porter RM]. IL-1Ra gene transfer potentiates BMP2-mediated bone healing by redirecting osteogenesis toward endochondral ossification. Molecular therapy : the journal of the American Society of Gene Therapy. 2022. PMID: 36245128. PMCID: PMC9931547.
• He T, Zhang C, Colombani T, [et al., including Porter RM]. Intra-articular kinetics of a cartilage targeting cationic PEGylated protein for applications in drug delivery. Osteoarthritis and cartilage. 2022. PMID: 36241136. PMCID: PMC9892226.
• Ferreira E, Gatrell LB, Childress L, [et al., including Porter RM]. A Transgenic Rat for Noninvasive Assessment of Chondrogenesis in Vivo. Cartilage. 2021:19476035211057243. PMID: 34809478. PMCID: PMC8804729.
• Almeida M, Kim HN, Han L, [et al., including Porter RM]. Increased marrow adipogenesis does not contribute to age-dependent appendicular bone loss in female mice. Aging cell. 2020:e13247. PMID: 33048436. PMCID: PMC7681065.
• He T, Zhang C, Vedadghavami A, [et al., including Porter RM]. Multi-arm Avidin nano-construct for intra-cartilage delivery of small molecule drugs. Journal of controlled release : official journal of the Controlled Release Society. 2020 318:109-123. PMID: 31843642. PMCID: PMC7424591.